Category: Allergan Inc.Syndicate content

Will Medtronic abandon inversion in Covidien deal? | Medtech Wall Street news for the week of August 18, 2014

August 21, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump

Will Medtronic follow Walgreen and abandon inversion in Covidien deal?

August 15, 2014 by Brad Perriello

Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover

August 20, 2014 by Brad Perriello

Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.

Report: Allergan solicits Salix in bid to thwart hostile Valeant takeover

Medtronic CEO Ishrak seeks to reassure employees on MDT-COV deal | The week in medtech M&A

August 20, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal; Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; Medtronic founder Bakken backs Covidien buy; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Allergan CFO Edwards steps down amid hostile Valeant takeover bid

Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal

August 15, 2014 by Brad Perriello

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

August 18, 2014 by Brad Perriello

Allergan CFO Jeff Edwards is stepping down amid a $44 billion hostile takeover bid from Valeant Pharmaceuticals and Pershing Square Capital Management.

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

Allergan (NYSE:AGN) said today that longtime CFO Jeff Edwards is stepping down to honor a commitment he made to his family earlier this year, replaced by treasurer Jim Hindman effective immediately.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

August 14, 2014 by Brad Perriello

The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO

Allergan calls out Valeant on latest earnings report : The week in medtech M&A

August 13, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Valeant's hostile takeover hopes fade as Allergan war continues; Medtronic hires ex-Senators to lobby for Covidien deal; FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; St. Jude closes $200M NeuroTherm buy; Medtronic-Covidien merger means tax hit for all stockholders, including execs

Report: Valeant's hostile takeover hopes fade as Allergan war continues

August 6, 2014 by Arezu Sarvestani

Allergan attacks activist investor's latest earnings report

Feds take a closer look at Valeant's hostile bid for Allergan

August 11, 2014 by Arezu Sarvestani

The FTC issued a "Second Request" for more information about Valeant Pharmaceuticals' ongoing attempts to take over Allergan.

Feds take a closer look at Valeant's hostile bid for Allergan

Federal authorities are taking a closer look at Allergan's (NYSE:AGN) ongoing battle to keep unrequited acquirer Valeant Pharmaceuticals at bay.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp